Qiu Guangbin, Li Yunhui, Liu Zheng, Wang Mengran, Ge Jingjing, Bai Xiaozhong
Department of Laboratory Medicine, No. 202 Hospital of PLA, Guangrong Street, No. 5, Shenyang, 110003, China.
Med Oncol. 2014 Dec;31(12):316. doi: 10.1007/s12032-014-0316-x. Epub 2014 Nov 6.
Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies in the head and neck region. Recently, aberrantly expressed high-mobility group box 1 (HMGB1) has received a great deal of attention as a potential biomarker for cancer diagnosis and prognosis. Therefore, the aim of this study was to estimate HMGB1 levels in serum in LSCC patients and healthy controls and evaluated the potential of serum HMGB1 as a noninvasive biomarker for diagnosis and prognosis in LSCC. Serum HMGB1 levels were analyzed in 71 LSCC patients and 50 healthy controls. The serum HMGB1 level was significantly higher in LSCC patients compared with the healthy controls (4.81 ± 2.33 vs. 3.21 ± 1.08 ng/mL, P < 0.001). High serum HMGB1 was significantly associated with T classification (P = 0.005), N classification (P = 0.002), and clinical stage (P = 0.001). The area under ROC curve was 0.716, and the sensitivity and specificity were 42.3 and 92.0%, respectively. The Kaplan-Meier plots showed that patients with high serum HMGB1 had a poorer overall survival than those with low serum HMGB1 (P = 0.036). Serum HMGB1 levels are significantly associated with the progression of LSCC. In this population, HMGB1 has a poor sensitivity, but a high specificity for the diagnosis of LSCC. Serum HMGB1 level has potential as a biomarker for the prognosis in LSCC patients.
喉鳞状细胞癌（LSCC）是头颈部最常见的恶性肿瘤之一。近年来，异常表达的高迁移率族蛋白B1（HMGB1）作为一种潜在的癌症诊断和预后生物标志物受到了广泛关注。因此，本研究的目的是评估LSCC患者和健康对照者血清中的HMGB1水平，并评估血清HMGB1作为LSCC诊断和预后的非侵入性生物标志物的潜力。对71例LSCC患者和50例健康对照者的血清HMGB1水平进行了分析。与健康对照者相比，LSCC患者的血清HMGB1水平显著更高（4.81±2.33对3.21±1.08 ng/mL，P<0.001）。高血清HMGB1与T分期（P=0.005）、N分期（P=0.002）和临床分期（P=0.001）显著相关。ROC曲线下面积为0.716，敏感性和特异性分别为42.
